

Report from EGM in Affibody Medical

Affibody Medical AB (publ) held an Extraordinary General Meeting today, 16 December 2021.

The Extraordinary General Meeting resolved, in addition to the members elected at the annual general meeting, to elect Camilla Sønnerby and Anders Martin-Löf as members of the Board of Directors for the period until the end of the next annual general meeting. It was further resolved that fees to the Board of Directors for the period until the next annual general meeting shall be paid in an amount of SEK 105,000 (corresponding to SEK 250,000 on a full-year basis) to each of the new members. In addition, it was resolved that a fee of SEK 42,000 (corresponding to SEK 100,000 on a full-year basis) shall be paid to the chairman of the audit committee for the period until the next annual general meeting.

Camilla Sønnerby was born in 1972 and is a Danish citizen. Camilla is currently a member of the Board of Directors of F2G Ltd and Healthcare Adviser for EQT Partners. She has more than 20 years' experience from leading positions in international pharmaceutical companies such as Takeda, Shire, Abbott, Roche and Schering Plough. Camilla has substantial experience from commercializing pharmaceuticals, but also from research and development, patient safety matters and IR. Camilla has a degree in Political Science from the University of Copenhagen. Camilla Sønnerby is considered independent in relation to Affibody and its senior management and in relation to Affibody's major shareholders.

Anders Martin-Löf was born in 1971 and is a Swedish citizen. Anders is currently a member of the Board of Directors of Cantargia AB. Anders has long experience as CFO of companies listed at the Stockholm Stock Exchange and has previously been CFO of Oncopeptides AB, Wilson Therapeutics AB and RaySearch Laboratories AB. He has also been responsible for investor relations and has held various business development positions at Swedish Orphan Biovitrum. Anders has a M.Sc. in Economics and Business from Stockholm University and a M.Sc. in Engineering Physics from the Royal Institute of Technology in Stockholm. Anders Martin-Löf is considered independent in relation to Affibody and its senior management and in relation to Affibody's major shareholders.